apixaban

Ligand id: 6390

Name: apixaban

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: apixaban

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 110.76
Molecular weight 459.19
XLogP 2.43
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Direct factor Xa inhibitor for treatment of venous thromboembolism, such as that experienced following hip or knee replacement surgery, or clots in the brain or other organs. In August 2014 the US FDA granted additional approval for this drug to be used to both treat, and reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE).
Mechanism Of Action and Pharmacodynamic Effects
This family of drugs inhibits coagulation without using antithrombin as a mediator. They are competitive inhibitors of free and clot bound factor Xa, which blocks the amplification of the coagulation cascade, preventing thrombus formation.
External links